Latest From Medicure Inc.
Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.
Zydus Cadila is teaming up with Canada’s Medicure Inc to launch cholesterol control medication Zypitamag, its first branded drug in the key US market, as the Indian firm drives ahead with a strategy of diversifying from low-priced generics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
FDA-approved labeling includes boxed warning for depression and suicidality, though this is specific for Huntington's disease patients, who are prone to these conditions.
- Therapeutic Areas
- Lariat Capital Inc.
- North America
- Parent & Subsidiaries
- Medicure Inc.
- Senior Management
Albert D Friesen, PhD, Chmn. & CEO
James Kinley, CFO
Neil Owens, PhD, Pres. & COO
- Contact Info
Phone: (204) 487-7412
2-1250 Waverly St.
Winnipeg, R3T 6C6
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.